3-(2-methoxyphenoxy)-N-methyl-3-phenylpropylamine,
3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine,
DL-N-methyl-3-(o-methoxyphenoxy)-N-methyl-3-phenylpropylamine,
Lilly 135252,
Lilly 94939,
LY 135252,
LY 94939,
LY-135252,
N-methyl-gamma-(2-methylphenoxy)phenylpropanolamine,
nisoxetine,
nisoxetine hydrochloride,
nisoxetine hydrochloride, (+-)-isomer,
nisoxetine, (+-)-isomer,
NISOXETINE HYDROCHLORIDE,
57754-86-6,
Nisoxetine Inhibitor,
Nisoxetine HCl,
3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine hydrochloride,
Benzenepropanamine, gamma-(2-methoxyphenoxy)-N-methyl-, hydrochloride, (+-)-,
SMR000326908,
SR-01000075280,
Lilly 94939,
NSC 298819,
AC1Q3DNE,
AC1L34MR,
MLS000860050,
MLS002222190,
SCHEMBL467262,
CHEMBL1256695,
Nisoxetine hydrochloride_x000D_,
DTXSID00110037,
HMS1570F22,
BCP28059,
Tox21_500901,
BN0383,
NSC298819,
3-(2-methoxyphenoxy)-n-methyl-3-phenylpropan-1-amine hydrochloride(1:1),
AKOS015896614,
API0008870,
CCG-220910,
CCG-222205,
LP00901,
NSC-298819,
NCGC00094216-01,
NCGC00094216-02,
NCGC00261586-01,
LS-31022,
LY-94,939,
EU-0100901,
FT-0630345,
N-151,
Nisoxetine hydrochloride, solid, >=98% (HPLC),
I06-2301,
SR-01000075280-1,
SR-01000075280-3,
SR-01000075280-6,
(+/-)-?-(2-Methoxyphenoxy)-N-methylbenzenepropanamine hydrochloride,
3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine;hydrochloride,
( inverted exclamation markA)-|A-(2-Methoxyphenoxy)-N-methyl-benzenepropanamine hydrochloride,
Nisoxetine,
UNII-9X76P2Y0EM,
9X76P2Y0EM,
C(CCNC)(Oc1ccccc1OC)c2ccccc2,
C17-H21-N-O2.Cl-H,
AR-1E6322,
CID134453,
59-49-4,